LabStyle Innovations to Present New Case Study at 5th EAI International Conference on Wireless Mobile Communication and Healthcare in London on October 15, 2015
Oct 12, 2015
LabStyle Innovations Corp. (OTCQB: DRIO), developer of the Dario™ Diabetes Management Solution, today announced its Medical Director, Dr. Moshe Kamar, will present a patient case study at MobiHealth's 5th EAI International Conference on Wireless Mobile Communication and Healthcare. Focused on, "Transforming healthcare through innovations in mobile and wireless technologies," the conference will take place in London, England from October 14 - 16, 2015. The conference is endorsed and organized by the European Alliance for Innovation (EAI).
At 5:20 pm on Thursday, October 15th, Dr. Kamar will deliver his presentation titled, "Smartphone Application for Self Blood Glucose Monitoring & Disease Management - A Case Report."
"We look forward to presenting data in this case study that shows how use of the Dario Smart Meter for the daily management of diabetes improved the performance and the overall health of a 55 year old male patient with Type 2 diabetes. The study concludes that mobile technologies, together with a multidisciplinary approach may revolutionize the management of diabetes,"
stated LabStyle President and CEO Erez Raphael. "Dario is marketed in several countries in Europe and is reimbursed for patients with diabetes in most of these regions. We are planning to launch in many other European countries in the coming quarters and we believe this case study data will support the Dario's market penetration in Europe and globally."
About LabStyle Innovations
LabStyle Innovations Corp. (OTCQB: DRIO) develops and commercializes patent-pending technology providing consumers with laboratory-testing capabilities using smart mobile devices. LabStyle's flagship product is the Dario™ personalized smart meter. Dario™ received CE mark certification in September 2013 and began a world rollout in select countries in December 2013. LabStyle filed a Premarket Notification Application, also known as a 510(k), with the US Food and Drug Administration (FDA) for the Dario™ smart meter (Dario™ Blood Glucose Monitoring System) in December 2013. LabStyle is pursuing patent applications in multiple areas covering the specific processes related to blood glucose level measurement as well as more general methods of rapid tests of body fluids using mobile devices and cloud-based services. For more information: http://www.mydario.com and http://mydario.investorroom.com the content of which is not part of this press release.
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and partners of LabStyle Innovations Corp. (the "Company") related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. For example, we are using forward looking statements in this press release when we discuss the study's conclusion that mobile technologies, together with a multidisciplinary approach may revolutionize the management of diabetes, when we discuss our plans to launch Dario in many other European countries in the coming quarters, or our belief that this case study data will support the Dario's market penetration in Europe and globally.. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dario™ as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.
For further information: .